Charles River Laboratories International (CRL) has cut its 2026 GAAP earnings guidance and reported a quarterly net loss, after recording divestiture related charges alongside slightly lower revenue compared with the same period last year.

Despite lowering 2026 GAAP EPS guidance and reporting a quarterly net loss, Charles River Laboratories International’s recent share price momentum has been strong, with a 90 day share price return of 58.79% and a 1 year total shareholder return of 79.84%, although the 5 year total shareholder return is down 34.95%.

If this kind of rebound catches your eye, it can help to widen the lens and see what else is moving in related areas, including 43 healthcare AI stocks.

After such a sharp rebound in Charles River Laboratories International, it matters whether recent optimism has already priced in the reset earnings outlook or whether the lower 2026 guidance still leaves meaningful upside on the table.

Most Popular Narrative: 14.7% Undervalued

Compared with the last close of $267.49, the most followed narrative for Charles River Laboratories International points to a fair value of $313.61, which frames the recent rebound in a very different light.

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier

On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry. However, the deeper implication is far more significant.

According to AnimalDoctorKwon, this valuation leans heavily on how primate supply constraints shape pricing power, margin potential, and the long term earnings profile that underpins that $313.61 figure. The key ingredients are revenue growth assumptions, a step change in profitability, and a future earnings multiple that treats this primate capacity as a scarce asset rather than a commodity service.

Result: Fair Value of $313.61 (UNDERVALUED)

However, this Charles River Laboratories International narrative could be hit by tighter NHP regulation or ethical pushback, as well as by weaker demand for primate based preclinical work.

Another View on Charles River Laboratories International

There is a very different picture when using the SWS DCF model for Charles River Laboratories International. On this view, the stock at $267.49 is trading well above an estimated future cash flow value of $49.09, which points to an overvalued outcome rather than a 14.7% discount. Which lens do you trust more when expectations are this far apart?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split on Charles River Laboratories International, this is the moment to look through the data yourself and act on your own judgment using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Charles River Laboratories International?

Do not stop with Charles River Laboratories International. Use the Simply Wall Street Screener to spot other opportunities that match your style before they move without you.

• Hunt for mispriced quality by checking companies that feature in the 52 high quality undervalued stocks.
• Build steadier income potential by reviewing stocks in the 8 dividend fortresses.
• Prioritise resilience and capital protection by focusing on companies highlighted in the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.